TerminatedPhase 4

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

Stopped: Due to nationwide shortage of Aminophylline. Enrolled subjects did not complete study.

United States248 participantsStarted 2010-11

Plain-language summary

The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at Rush University Medical Center Exclusion Criteria: * Patient refusal to participate * Known allergic reaction to aminophylline. * Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting. * Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms. * Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week. * Pregnant or breast-feeding women. * Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).

What they're measuring

Composite Endpoints of Abdominal Cramps and Diarrhea.

Timeframe: within 2 hours from the intervention.

Trial details

NCT IDNCT01250496

SponsorRush University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-11

Results submitted2012-11-29

View on ClinicalTrials.gov More Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan trials